BioAlliance Pharma: Two New Appointments to BioAlliance Pharma's Supervisory Board in Phase with the Company's Development.PARIS Paris, in Greek mythology Paris or Alexander, in Greek mythology, son of Priam and Hecuba and brother of Hector. Because it was prophesied that he would cause the destruction of Troy, Paris was abandoned on Mt. -- Regulatory News: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care supportive care, n medical and other interventions that attempt to support and make comfortable rather than to cure. of cancer and AIDS patients, today announced the appointment of two new Board members. The Supervisory Board has co-opted Andre Ulmann MD, PhD (founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of HRA HRA Health Reimbursement Arrangement HRA Health Risk Assessment HRA Housing and Redevelopment Authority HRA Human Resources Administration HRA Health Reimbursement Account HRA Housing Revenue Account Pharma since 1996) and the company ING Belgium (represented by Denis Denis, king of Portugal: see Diniz. Biju-Duval, BEng, MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration , Head of ING Belgium's private equity team since 2001) following the departure of Georges Hibon and Philippe Taranto. "I wish to thank Georges Hibon and Philippe Taranto for their work, which greatly benefited from their international experience in pharmaceuticals and finance" stated Dominique Costantini, President and CEO, BioAlliance Pharma. New Board member Andre Ulmann will contribute his entrepreneurial experience within HRA, a fast-growing European company which develops and commercializes drugs in the reproductive health and endocrinology markets. Furthermore, the core BioAlliance Pharma shareholder ING Belgium has confirmed its midterm commitment to the company. "I am delighted to welcome these two major players with a reinforced presence of major shareholders in the Supervisory Board", stated Jean-Marie Zacharie, Chairman of the Supervisory Board. "With their support BioAlliance Pharma will continue to strengthen its growth strategy", added Dominique Costantini. Furthermore, AGF AGF Assurances Générales de France AGF Army Ground Forces AGF American Growth Fund (mutual fund) AGF American General Finance AGF Arbeitsgemeinschaft der Grossforschungseinrichtungen AGF Anatomic Gift Foundation AGF Assume Good Faith Private Equity (another core shareholder and a current Board member) has appointed Remi Droller droll adj. droll·er, droll·est Amusingly odd or whimsically comical. n. Archaic A buffoon. [French drôle, buffoon, droll, from Old French drolle (Partner, managing investments in Healthcare) as its permanent representative. Remi Droller holds an M.Phil. in Molecular Biology and a Masters in Innovation Management. About BioAlliance Pharma As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. For more information, visit the BioAlliance Pharma web site at http://www.bioalliancepharma.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque ris·qué adj. Suggestive of or bordering on indelicacy or impropriety. [French, from past participle of risquer, to risk, from risque, risk; see risk.] Adj. ") section of the 2008 Reference Document filed with the AMF AMF ACE (Allied Command, Europe) Mobile Force AMF Autorité des Marchés Financiers (French) AMF Action Message Format AMF Arab Monetary Fund AMF Asian Monetary Fund AMF Autocrine Motility Factor on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com). |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion